Glucarpidase allows for outpatient administration of high-dose methotrexate during COVID-19 pandemic

Presenting preliminary data at SNO2020, researchers showed that glucarpidase allows for outpatient administration of high-dose methotrexate (HD-MTX) in patients with CNS lymphoma.

“Patients with CNS lymphoma receiving first-line HD-MTX require hospitalization for monitoring and aggressive hydration to prevent toxicity,” said Dr Lauren Schaff of Memorial Sloan Kettering Cancer Center in New York, New York, USA. However, this may not be possible during the COVID-19 pandemic. “When the local incidence of COVID-19 is high, hospital resources are limited and there is an effort to limit patient contact with the healthcare system,” she said.